Hengrui Pharma to Present Research at ESMO Congress
The pharmaceutical company will showcase 64 research findings in Madrid from October 23 to 27, 2026.
Updated on Oct. 20, 2026 in Cancer
Live Poll
Are global research efforts effectively improving long-term survival outcomes for cancer patients?
Hengrui Pharma is set to present 64 research findings at the upcoming ESMO Congress in Madrid, Spain. The event will take place from October 23 to 27, 2026, marking the eleventh consecutive year of the company's participation.
Why it matters
The company's presence highlights its ongoing clinical development efforts, including progress on ruzaltatug rezetecan and HRS-4642. Sharing these findings allows the global medical community to evaluate new therapeutic candidates for advanced cancers.
Hengrui Pharma will deliver 64 research findings, including three Proffered Paper presentations and three Rapid Oral presentations. The company will also display 32 posters and 26 e-posters to international attendees.
The players
Hengrui Pharma
Hengrui Pharma is a global pharmaceutical company focused on the research, development, and commercialization of oncology and autoimmune disease treatments.
ESMO Congress
The ESMO Congress is an annual meeting organized by the European Society for Medical Oncology that serves as a platform for presenting the latest cancer research.
The details
The program covers a wide range of oncology research, including work on ruzaltatug rezetecan, which recently received FDA Fast Track designation for EGFR-mutated metastatic NSCLC. Additionally, HRS-4642 has been granted breakthrough therapy designation in China for first-line treatment of specific pancreatic cancer.
Timeline
July 2026: China's National Medical Products Administration accepted a marketing application for ruzaltatug rezetecan.
October 23, 2026: The ESMO Congress commences in Madrid.
October 27, 2026: The ESMO Congress concludes.
The Big Picture
This presentation cycle follows the standard dissemination practices of the ESMO Congress scientific program. The company's participation reflects the established pattern of pharmaceutical firms using major oncology forums to publicize trial data and regulatory milestones.
These findings provide insight into the pipeline for potential new treatments for NSCLC and pancreatic cancer. Patients and healthcare providers can monitor these results for progress toward future therapeutic approvals.
The takeaway
The event serves as a significant window into the future of oncology treatments currently under investigation. These results contribute to the broader body of clinical evidence that may eventually shape standard care protocols for metastatic cancers.
Further reading
For more information on the latest developments in oncology, visit the Cancer section.
Live Poll
Are global research efforts effectively improving long-term survival outcomes for cancer patients?
